Carl E. Clay, PhD
Regional Scientific Medical Affairs Manager
Washington University School of Medicine, Post-doctoral Fellow, 2002-2003
Wake Forest School of Medicine-Wake Forest University, Ph.D., 2002
University of Colorado, BS, 1996
Apoptosis in breast cancer cells.Support the development of clinical publications for cardiovascular and diabetes products. I have been involved with the successful launch of the diabetes treatment Onglyza (saxagliptin), and I am involved with upcoming therapies such as dapagliflozin, ticagrelor, Certriad, and PN400.
Clay CE, Namen AM, Atsumi G, Trimboli AJ, Fonteh AN, High KP, Chilton FH. (2001) The magnitude of PPARg activation is associated with important and seemingly opposite biological responses in breast cancer cells. Journal of Investigational Medicine 49, 413-420.
Clay CE, Atsumi G, High KP, Chilton FH. (2001) Early de novo gene expression is required for 15deoxyD12,14 prostaglandin J2 induced apoptosis in breast cancer cells. The Journal of Biological Chemistry 276, 47131-47135.
Monjazeb AM, Clay CE, High KP, Chilton FH. (2002) Antineoplastic properties of arachidonic acid and its metabolites. Prostaglandins Leukot Essent Fatty Acids. 66, 5-12.
Clay CE, Thorburn J, High KP, Chilton FH. (2002) 15deoxyD12,14 prostalgandin J2-induced apoptosis does not require PPARg breast cancer cells. The Journal of Lipid Research. 43, 1818-1828.
O'Flahrety JT, Rogers LC, Paumi CM, Hantgan RR, Clay CE, Chen YQ, Willingham MC, Smitherman PK, Kute TE, Rao A, Cramer SD, Morrow CS. (2005) Bidirectional effects of 5-HETE analogs on the proliferation of cancer cells. 1736, 228-236.
For a listing of additional publications, refer to PubMed, a service provided by the National Library of Medicine.